Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a RSV challenge study of intranasal MV-012-968 vaccine
2020-002848-22Phase 2Unknown
- Sponsor
- Meissa Vaccines
- Start
- Jul 2020
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing MV-012-968 intranasal vaccine with Placebo intranasal control (2 arms). Primary endpoint: Primary: Frequency of symptomatic RSV infection (Days 2–12). Status: unknown.
02
Drugs
MV-012-968
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2020-002848-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002848-22.